Treatment of gram-negative shock.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001442:Bacteroides Infections / Q000628:therapy; D002512:Cephalothin / Q000008:administration & dosage / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D004754:Enterobacter; D004927:Escherichia coli Infections / Q000628:therapy; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007545:Isoproterenol / Q000627:therapeutic use; D007612:Kanamycin / Q000008:administration & dosage / Q000627:therapeutic use; D007938:Leukemia / Q000150:complications; D008297:Male; D008875:Middle Aged; D011512:Proteus Infections / Q000628:therapy; D011552:Pseudomonas Infections / Q000628:therapy; D012480:Salmonella Infections / Q000628:therapy; D012705:Serratia; D012772:Shock, Septic / Q000150:complications / Q000628:therapy*; D013290:Streptococcal Infections / Q000628:therapy; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014882:Water-Electrolyte Balance
D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D000900:Anti-Bacterial Agents; D003911:Dextrans; D005938:Glucocorticoids; D014662:Vasoconstrictor Agents; D007612:Kanamycin; D000667:Ampicillin; D007545:Isoproterenol; D002512:Cephalothin; D006854:Hydrocortisone